When “Not Covered” Isn’t the Last Word

Pharmaceutical vice presidents, executive directors, brand leads, marketing leads, and commercial leads:

The rejection that gets read as final

Of all the ways a prescription can stall on its way to a patient, one feels the most final: the claim comes back not covered. A benefit exclusion. The drug is not on the formulary, the claim rejects at the pharmacy, and the prescription stops moving.

It reads like the plan’s last word. Prior authorization, a team will chase. A missing diagnosis code, they will correct. But “not covered” sounds like a decision already made—a closed door, nothing left to do. The prescription gets written off, and the patient never starts therapy.

For a meaningful share of these prescriptions, that reading is mistaken. A “not covered” rejection describes a status at one moment in the claim, not a final verdict on coverage. And the reason so many of them stay lost is not that the door is locked. It is that no one positioned to act on it ever sees it open.

This is how formularies are being managed now.

Start with why there are so many of these rejections in the first place, because it is not an accident or an edge case. Managing access through coverage decisions is a deliberate, growing instrument of benefit design; and it is intensifying across both commercial and Medicare plans, through somewhat different tools.

On the commercial side, outright exclusion is the visible edge. For 2026, the three largest pharmacy benefit managers—Caremark, Express Scripts, and Optum Rx—each excluded more than 600 drugs from their standard formularies.[1] This is not a sudden spike; it is the latest point on a long climb. In 2014, CVS Caremark and Express Scripts together excluded 134 medications. By 2020, the three largest PBMs excluded nearly 1200 combined, and more than 1300 the following year.[2] A decade of steadily widening exclusion lists is not random variation. It is benefit design working as intended.

In Medicare, the same pressure shows up in a different mix. As the Inflation Reduction Act’s new out-of-pocket cap took effect in 2026, plans facing the resulting cost pressure tightened formulary management—top brand-drug coverage declined modestly, while plans leaned harder on the levers around coverage: a sharp rise in coinsurance tiers and increasing use of prior authorization on covered brands.[3] The instrument differs from the commercial exclusion list, but the direction is the same: access managed more tightly each year, with more prescriptions failing to clear at the counter as a result.

For a brand team, the point is not that any of this is unfair. That is a separate argument. It is that “not covered” and the access friction surrounding it is now a routine outcome of how benefits are designed, not a rare event. Which makes the next fact matter more, not less.

A rejection is a status, not a sentence.

Here is what gets lost in the word “excluded”: A formulary exclusion blocks a specific product on a recommended formulary—and those recommendations are not absolute. As the industry’s most cited PBM analysis puts it plainly, a drug’s appearance on an exclusion list does not guarantee that all patients lose access; plan sponsors can choose not to adopt their PBM’s standard exclusions, and individual cases can move through exception pathways.[1]

That gap between “on the exclusion list” and “truly unavailable to this patient” is where recoverable prescriptions live. A “not covered” rejection frequently turns out to be a resolvable status rather than a true ineligibility for reasons that fall into a few recognizable buckets:

• The step was not met yet. A step therapy requirement means a preferred agent has to be tried or documented first. The drug is not barred; the sequence was not satisfied when the claim ran.

• The documentation was incomplete. A missing or mismatched diagnosis code, absent chart notes, or a gap in the record can present as a coverage problem when the underlying issue is paperwork.

• The site of care was wrong. Coverage exists, but only through a specific channel or specialty pharmacy. Redirecting the claim resolves it.

• A covered alternative exists within the same mechanism of action. The specific product is not preferred, but an on-formulary option in the same class is—and a formulary exception or therapeutic interchange opens the path.

None of this is exotic. It is the everyday texture of benefit design. But each case means a rejection that looks terminal is, in fact, a rejection with a route through it.

The evidence that “rejected” is not always the end of the story

The clearest sign that these prescriptions are recoverable is how often rejected claims get approved once someone works them.

National claims data tells the story plainly. In IQVIA’s analysis of newly launched specialty medicines, 52% of claims were rejected by the original payer; yet 61% were ultimately approved and filled.[4] A first rejection, in other words, is routinely not the final answer.

The pattern repeats in disease-specific data. In a recent claims study of blood-cancer patients, insurers initially rejected roughly 65% of specialty oral oncology claims in Medicare and 84% commercially, largely on prior authorization or formulary restrictions—yet approval rose to 85% in Medicare by 90 days.[5] The initial rejection rate and the eventual approval rate describe the same prescriptions. The gap between them is recoverable volume.

And when denials are formally challenged, they reverse more often than most expect. Reviews of appeal outcomes report that well-documented prior authorization appeals are overturned in a majority of cases and that peer-to-peer reviews reverse more than half of denials.[6] The pattern holds across the very mechanisms—step therapy, formulary status, medical necessity—that produce “not covered” rejections in the first place.

None of this means every rejection is winnable. It means a rejected claim and a truly ineligible patient are not the same thing, and the industry’s own data has been saying so for years.

So why do the recoverable ones stay lost?

Here is where the recoverable prescriptions slip away. A rejection that can be resolved only gets resolved if someone acts on it. But the people positioned to act usually never learn it happened.

Think about where the rejection lands. The prescribing decision was made correctly in the clinical encounter. The script was sent. It rejected downstream, at the pharmacy, against the plan’s rules—well after the prescriber moved on to the next patient. The prescriber is not told. The field team does not see claims. The hub does not hear about it unless the patient calls to say something went wrong. The rejection surfaces in a place none of them are looking.

And this is exactly why the clinical workflow has to be understood as more than the EHR. The EHR and the tools layered onto it center on the moment of ordering. Some now reach a step or two further, flagging coverage issues or starting an electronic prior authorization. But a benefit exclusion rejection lands later and elsewhere: at the pharmacy, after the order is placed. In many cases, the tools that extend past ordering still do not carry this particular event back to the prescriber in a form that prompts action while the claim can still be worked. The prescriber is not ignoring the problem. The systems meant to keep the care team informed were not watching the place where it surfaced.[7]

The consequence is quiet but expensive: From where you sit, an addressable “not covered” and a truly final “not covered” look identical. Both show up as a script that was written and never filled. The recoverable ones are camouflaged inside the total loss, indistinguishable from the genuinely ineligible—so the whole group gets written off together.

That is the misdiagnosis. The barrier is not that these prescriptions cannot be recovered. It is that the recoverable ones are invisible to everyone who could recover them.

What changes when the friction becomes visible?

Separate the two problems and the picture shifts. Addressability and visibility are not the same thing, and the benefit exclusion bucket has mostly been failing on visibility.

When a rejection is detected as it happens and the prescriber and their team are notified with the specific reason and the path to resolve it, the recoverable subset finally gets the chance it never had. The claim that rejected on a missing diagnosis code, an unmet step, the wrong pharmacy, or a formulary status with an exception path becomes something a person can act on—while the claim can still be worked, before the patient has moved on.

“Not covered” still means something. Some of those rejections are genuinely final. But a meaningful share are a status the plan returned in a moment, recoverable to exactly the degree that someone can see it in time to act.

ReCaptRx^™ was built for exactly this.

This is the gap, and it is the one ReCaptRx was built to close.

The reach is already there. ReCaptRx operates across an opted-in clinician network reaching millions of NPIs, notifying prescribers and their teams through the channels they already use—no new login, no portal to learn, the message arriving where the work actually happens.

What that reach makes possible is visibility into the rejections that were previously invisible. Across the program, benefit exclusion and coverage rejections are detected as they occur and surfaced to the people who can act on them, turning a silent failure at the pharmacy counter into a notification with a reason and a resolution path attached.

The Prescription Journey Audit is where this starts: a structured look at where and why prescriptions are lost between prescribing and dispensing, sizing how much of the loss is addressable before a single notification is sent. The audit identifies the leakage. ReCaptRx recovers it.

The rejections that looked final turn out to be exactly as recoverable as they are visible. The work is making them visible in time to the people who can still do something about it.

Dave Dierk is Co-President of Aventria Health Group and a 30-year thought leader in pharmaceutical sales and marketing. If your brand is losing prescriptions to “not covered” rejections that may be recoverable, Dave welcomes the conversation: dave.dierk@aventriahealth.com.

References

1. Fein, AJ. The Big Three PBMs’ 2026 Formulary Exclusions: MFP, Private Label Biosimilars, and Direct-to-Patient Threats for PBMs. Drug Channels. Accessed June 25, 2026. https://www.drugchannels.net/2026/01/the-big-three-pbms-2026-formulary.html

2. MHE Staff. The rise in formulary exclusions. Manag Healthc Exec. 2021;31(5). Accessed June 25, 2026. https://www.managedhealthcareexecutive.com/view/the-rise-in-formulary-exclusions

3. Avalere Health. Part D Formulary Management Tightens in 2026. November 10, 2025. Accessed June 25, 2026. https://advisory.avalerehealth.com/insights/part-d-formulary-management-tightens-in-2026

4. Shaw G. Half of Novel Specialty Prescriptions Go Unfilled, IQVIA Data Show. Presented at National Association of Specialty Pharmacy (NASP) 2025. Spec Pharm Contin. April 10, 2026. Accessed June 25, 2026. https://www.specialtypharmacycontinuum.com/Policy/Article/12-25/Specialty-Prescriptions-Unfilled-IQVIA-Data-Findings/78959

5. Myshko D. Most blood cancer patients initially denied coverage for oral medications. Manag Healthc Exec. June 16, 2026. Accessed June 30, 2026. https://www.managedhealthcareexecutive.com/view/most-blood-cancer-patients-initially-denied-coverage-for-oral-medications

6. Clark C. Huge rates of insurance denials get overturned by independent review experts. MedPage Today. April 16, 2026. Accessed June 30, 2026. https://www.medpagetoday.com/publichealthpolicy/publichealth/120774

7. Aventria Health Group. How care teams actually work. Blog. Accessed June 30, 2026. https://www.aventriahealth.com/how-care-teams-actually-work